Bioprocessing White Papers

  1. Advancing Cell Culture Strategies To Accelerate Biologics Development 5/5/2026

    Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.

  2. Why Pharmaceutical Scientists Trust The Discovery Core Rheometer 5/1/2026

    Drug formulations demand more than single‑point viscosity data. Explore how rheology reveals stability, flow, and structural behavior across suspensions, topicals, and injectables.

  3. Expanding The Capabilities Of Targeted Integration 5/1/2026

    See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

  4. Fast Path To Market: Going From GMP1 To PPQ In Just 12 Months 4/30/2026

    Learn how focused optimization and coordinated execution helped overcome technical uncertainty and enable faster progression to market readiness.

  5. Standardized Extraction Protocol Per USP <665>: Bridging Regulatory Expectations And Industry Best Practices 4/29/2026

    View how to implement USP <665> extractables testing, align with global E&L standards, and apply risk-based strategies to ensure regulatory compliance and patient safety.

  6. Using Client Centricity As Fuel For Innovative Biologics Development And Manufacturing Solutions 4/23/2026

    Complex biologics require flexible development, advanced analytics, and quality by design. Learn how collaborative bioprocessing reduces risk, enables efficient scale‑up, and supports clinical success.

  7. Implementing Medium And High-Volume Drug Handling And Packaging Programs 4/23/2026

    Simplify the complexity of combination product development by partnering for integrated support across device design, industrialization, manufacturing, and final product assembly.

  8. Quality By Design Understanding And Securing Virus Clearance 4/22/2026

    Data-driven virus clearance improves risk assessment, process insight, and study design. Learn how Quality by Design cuts late-stage risk while strengthening regulatory confidence and viral safety.

  9. Cell Based Potency Assays: De-Risk Your Path With An Experienced CDMO 4/21/2026

    Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate the biopharmaceutical development landscape.

  10. De-Risk Nucleic Acid Therapeutics Through Strategic Outsourcing 4/20/2026

    Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality.